AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CTKB · NASDAQ · Medical - Devices

Cytek (CTKB)

Builds Aurora spectral flow cytometers that profile 30-plus markers per sample on benchtop hardware.

$5.71

After hours−0.01 (−0.17%)

At close$5.72(+8.33%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	48	58	45	47	52	57	41	46	52	62	44	48
Cost of revenue	21	25	22	21	22	24	21	22	25	29	23	20
Gross profit	27	33	23	25	29	34	20	24	28	33	21	28
	34	33	34	34	33	31	35	34	37	38	40	40
Research & development	11	11	10	10	10	10	10	9	9	9	10	10
	22	22	24	24	23	21	25	26	28	30	30	30
Selling & marketing	12	12	13	12	12	12	13	12	12	13	12	13
General & administrative	10	11	11	12	11	9	13	14	16	16	18	17
Operating income	−6	0	−11	−9	−4	3	−15	−11	−9	−6	−18	−11
	2	4	2	1	4	7	4	4	1	2	1	0
Interest income	2	1	1	1	1	6	1	1	1	1	1	1
Interest expense	1	0	0	0	0	0	0	0	0	1	0	0
Other non-operating income	−3	−5	−2	−1	−5	8	−4	−4	−2	−2	−1	0
Income before tax	−4	4	−9	−7	0	10	−11	−7	−8	−4	−17	−12
Income tax expense	2	−1	−3	3	−1	1	0	−1	−2	40	1	1
Net income from continuing operations	−6	6	−6	−10	1	10	−11	−6	−5	−44	−19	−12
Net income	−6	6	−6	−10	1	10	−11	−6	−5	−44	−19	−12
EPS, basic	−$0.05	$0.04	−$0.05	−$0.08	$0.01	$0.07	−$0.09	−$0.04	−$0.04	−$0.34	−$0.15	−$0.09
EPS, diluted	−$0.05	$0.04	−$0.05	−$0.08	$0.01	$0.07	−$0.09	−$0.04	−$0.04	−$0.34	−$0.15	−$0.09
Weighted average shares, basic	136	131	131	131	131	129	128	127	128	128	129	129
Weighted average shares, diluted	136	131	131	131	133	129	128	127	128	128	129	129
EBITDA	−1	7	−6	−5	3	−2	−8	−3	−4	0	−14	−8
Depreciation & amortization	3	2	2	2	3	3	3	3	3	3	3	3
EBIT	−4	5	−9	−7	0	−5	−11	−6	−7	−3	−17	−11